This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Biopharma Remove Leads Remove Pharma Remove Pharmaceutical products
article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

MARCH 14, 2024

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] The food sector has already initiated the publication of preliminary regulations aimed at restricting PFAS in packaging. [3].

Pharmaceutical 52
Pharmaceutical Manufacturing Food Healthcare Provider 52
article thumbnail

Practical advice for Early Scientific Advice (ESA) in HTA submissions

pharmaphorum

SEPTEMBER 28, 2022

In recent years, the biopharma market has become progressively complex. As a result, payers are feeling increased pressure to make the right decisions based on the perceived value of each product. HTA agencies can assist biopharma companies at the early stages of development to ensure they are meeting the expectations of payers.

Biopharma 52
Biopharma Side effects Consulting Pharmaceutical products 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024